Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 42

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
 30,(in millions)20252024Net income (loss)$2,222 $1,284 Adjustments to reconcile net income (loss) to cash provided by (used for) operating activitiesDepreciation and amortization1,003 921 Deferred and prepaid income taxes20 10 Stock-based compensation expense228 197 Goodwill and other intangible asset impairment charges46 276 Net loss (gain) on investments and notes receivable(181)60 Contingent consideration net expense (benefit)11 (4)Inventory step-up amortization127 — Fixed asset impairment73 30 Other, net22 (8)Increase (decrease) in operating assets and liabilities, excluding purchase accounting:Trade accounts receivable(171)(261)Inventories(138)(274)Other assets(103)(109)Accounts payable, accrued expenses and other liabilities11 (142)Cash provided by (used for) operating activities3,170 1,979 Investing activities:  Purchases of property, plant and equipment and internal use software(525)(513)Payments for acquisitions of businesses, net of cash acquired(1,504)(1,222)Payments for investments and acquisitions of certain technologies(180)(264)Proceeds for settlements of hedge contracts69 — Other, net11 17 Cash provided by (used for) investing activities(2,128)(1,983)Financing activities:  Payment of contingent consideration previously established in purchase accounting(62)(131)Payments for finance leases(49)(25)Payments on short-term borrowings(1,595)(504)Net increase (decrease) in commercial paper(196)— Proceeds from long-term borrowings, net of debt issuance costs1,558 2,145 Cash used to net share settle employee equity awards(128)(83)Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans262 202 Other, net(2)(4)Cash provided by (used for) financing activities(211)1,600 Effect of foreign exchange rates on cash39 (2)Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents870 1,594 Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period606 1,055 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,476 $